KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)

被引：0
|
作者：
Siefker-Radtke, A. O. [1 ]
Steinberg, G. [2 ]
Bedke, J. [3 ]
Nishiyama, H. [4 ]
Martin, J. [5 ]
Kataria, R. [5 ]
Frenkl, T. L. [5 ]
Hoimes, C. J. [6 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA
[2] NYU Langone Hlth, Neurosurg, New York, NY USA
[3] Univ Tubingen, Urol, Tubingen, Germany
[4] Tokyo Univ Scient, Ind Adm, Tokyo, Japan
[5] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[6] UH Cleveland Med Ctr, Med Oncol, Cleveland, OH USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
988TiP
引用
收藏
页码：401 / 401
页数：1
相关论文
共 50 条
  • [1] Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866
    Siefker-Radtke, Arlene O.
    Steinberg, Gary D.
    Bedke, Jens
    Nishiyama, Hiroyuki
    Fang, Xiao
    Kataria, Ritesh
    Moreno, Blanca Homet
    Hoimes, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [2] Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303
    Galsky, Matthew D.
    Hoimes, Christopher J.
    Necchi, Andrea
    Shore, Neal
    Witjes, J. Alfred
    Steinberg, Gary
    Bedke, Jens
    Nishiyama, Hiroyuki
    Fang, Xiao
    Kataria, Ritesh
    Sbar, Eric
    Jia, Xieyang
    Siefker-Radtke, Arlene
    FUTURE ONCOLOGY, 2021, 17 (24) : 3137 - 3150
  • [3] Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905
    Galsky, Matt D.
    Necchi, Andrea
    Shore, Neal D.
    Witjes, Fred
    Nam, Kijoeng
    Sbar, Eric
    Moreno, Blanca Homet
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [4] KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC)
    Galsky, M.
    Necchi, A.
    Shore, N. D.
    Witjes, F.
    Nam, K.
    Godwin, J. L.
    Frenkl, T. L.
    Plimack, E. R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] Perioperative enfortumab vedotin (EV) plus pembrolizumab (pembro) versus chemotherapy in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): Phase 3 KEYNOTE-B15/EV-304.
    Hoimes, Christopher J.
    Loriot, Yohann
    Bedke, Jens
    Nishiyama, Hiroyuki
    Kataria, Ritesh S.
    Moreno, Blanca Homet
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.
    Weickhardt, Andrew James
    Van der Heijden, Michiel Simon
    Balar, Arjun Vasant
    Shariat, Shahrokh F.
    Shore, Neal D.
    Fang Xiao
    Godwin, James Luke
    Kapadia, Ekta
    Michalski, Jeff M.
    James, Nicholas D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [7] Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992.
    Balar, Arjun Vasant
    James, Nicholas D.
    Shariat, Shahrokh F.
    Shore, Neal D.
    Van der Heijden, Michiel Simon
    Weickhardt, Andrew James
    Fang, Xiao
    Godwin, James Luke
    Kapadia, Ekta
    Michalski, Jeff M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).
    Necchi, Andrea
    Bedke, Jens
    Galsky, Matt D.
    Shore, Neal D.
    Plimack, Elizabeth R.
    Xylinas, Evanguelos
    Jia, Calvin
    Hennika, Tammy
    Moreno, Blanca Homet
    Witjes, Alfred Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [9] KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).
    Hoimes, Christopher J.
    Bedke, Jens
    Loriot, Yohann
    Nishiyama, Hiroyuki
    Fang, Xiao
    Kataria, Ritesh S.
    Moreno, Blanca Homet
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Phase II trial of neoadjuvant gemcitabine (G) and cisplatin (C) with sunitinib in patients (pts) with muscle-invasive bladder cancer (MIBC)
    Balar, Arjun Vasant
    Iyer, Gopa
    Apolo, Andrea Borghese
    Regazzi, Ashley Marie
    Garcia-Grossman, Ilana Rebecca
    Pendse, Deepa
    Ostrovnaya, Irina
    Chou, Joanne F.
    Bochner, Bernard
    Dalbagni, Guido
    Herr, Harry W.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345